Data Sheet (Cat.No.TMPY-07000)

TargetMol

PD-L1 Protein, Human, Recombinant (His), AF647-Labeled

General Information

Synonyms:	B7-H1;B7-H;B7H1;hPD-L1;PDL1;PDCD1L1;PD-L1;PDCD1LG1
Protein Construction:	A DNA sequence encoding the extracellular domain (Met 1-Thr 239) of human PD-L1 (NP_054862.1) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 647 (Excitation = 655 nm, Emission Max.= 680 nm).
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q9NZQ7-1
Molecular Weight:	31 kDa (predicted)

QC Testing

Biological Activity:	Flow cytometric analysis of anti-PD-L1 CAR expression. 293 cells were lentivirally transduced with anti-PD-L1 CAR. Flow cytometric analysis was performed with a negative control protein and PD-L1 Protein, Human, Recombinant (His), AF647-Labeled (Cat#TMPY-07000), respectively. Non-transduced 293 cells were used as a control (left).
Purity:	≥ 90% as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU per μg protein as determined by the LAL method.
Formulation:	This product is Lyophilized from sterile PBS, 5% Trehalose, 5% Mannitol, pH 7.4. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Preparation and Storage

Reconstitution:

Please refer to the lot-specific COA.

Stability & Storage:

Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Shipping:

In general, Lyophilized powders are shipping with blue ice.

Protein Background

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and

together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481